IntelliGenome and CTR Scientific Join Forces to Enhance CRISPR-TB Testing in Mexico
In a significant move to improve tuberculosis (TB) diagnostics in Mexico, IntelliGenome, Inc. has announced its strategic partnership with CTR Scientific (Control Técnico y Representaciones S.A. de C.V.). This collaboration is set to facilitate the evaluation, commercialization, and eventual adoption of the CRISPR-TB Blood Test across the country.
The partnership is particularly noteworthy as it positions CTR Scientific as the exclusive distribution partner for IntelliGenome’s CRISPR-TB test in Mexico. By leveraging CTR Scientific’s established network and expertise in the healthcare sector, the two companies aim to accelerate market development and create a pathway for the successful introduction of this innovative testing technology.
CRISPR-TB is a groundbreaking blood-based assay that identifies the presence of Mycobacterium tuberculosis using cell-free DNA (cfDNA). This advancement addresses a significant need in the medical community, as traditional sputum-based testing often fails to adequately serve certain populations, such as children, those with extrapulmonary TB, and other vulnerable groups. The introduction of this test could revolutionize how TB is detected, enabling quicker and more accurate diagnoses for individuals who might otherwise struggle to obtain care.
Kurt Wehrle, Vice President of Partnerships & Strategic Alliances at IntelliGenome, expressed optimism about the partnership, noting that Mexico represents a strategically vital market for advancing innovative diagnostic approaches. Wehrle stated, “Together with CTR Scientific, we look forward to generating clinical evidence, expanding access to CRISPR-TB, and supporting Mexico's efforts to improve tuberculosis detection.”
Alan R. Criollo Ródiz, the Clinical Diagnostics Manager at CTR Scientific, echoed this sentiment, emphasizing the company’s commitment to introducing high-value diagnostic innovations into the Mexican healthcare system. Criollo explained that their partnership with IntelliGenome would enhance the available TB diagnostic methods, particularly beneficial for children and other high-risk populations. “We are proud to support technologies that may expand access to timely and clinically meaningful TB detection in Mexico,” he added.
The CRISPR-TB test has already achieved CE-IVDD certification and holds regulatory registrations in multiple international markets, indicating a promising future for its adoption across Latin America. This partnership underscores both companies' dedication to addressing the pressing public health issue of tuberculosis, which remains a growing concern in many regions.
IntelliGenome specializes in developing cutting-edge CRISPR-based molecular diagnostics aimed at improving infectious disease detection and management, including tuberculosis. The collaboration with CTR Scientific, a renowned provider of diagnostic and laboratory solutions in Mexico, is expected to play a crucial role in advancing public health initiatives and healthcare infrastructure in the country.
In conclusion, this strategic alliance signifies a pivotal step towards enhancing TB detection and potentially transforming the lives of many individuals affected by this disease. By combining innovative technology with local expertise, IntelliGenome and CTR Scientific are poised to make a lasting impact in the fight against tuberculosis in Mexico. The relentless pursuit of improved diagnostics illustrates the potential for significant advancements in public health, paving the way for more effective and timely medical interventions for one of the world's most dangerous infectious diseases.
The partnership is particularly noteworthy as it positions CTR Scientific as the exclusive distribution partner for IntelliGenome’s CRISPR-TB test in Mexico. By leveraging CTR Scientific’s established network and expertise in the healthcare sector, the two companies aim to accelerate market development and create a pathway for the successful introduction of this innovative testing technology.
CRISPR-TB is a groundbreaking blood-based assay that identifies the presence of Mycobacterium tuberculosis using cell-free DNA (cfDNA). This advancement addresses a significant need in the medical community, as traditional sputum-based testing often fails to adequately serve certain populations, such as children, those with extrapulmonary TB, and other vulnerable groups. The introduction of this test could revolutionize how TB is detected, enabling quicker and more accurate diagnoses for individuals who might otherwise struggle to obtain care.
Kurt Wehrle, Vice President of Partnerships & Strategic Alliances at IntelliGenome, expressed optimism about the partnership, noting that Mexico represents a strategically vital market for advancing innovative diagnostic approaches. Wehrle stated, “Together with CTR Scientific, we look forward to generating clinical evidence, expanding access to CRISPR-TB, and supporting Mexico's efforts to improve tuberculosis detection.”
Alan R. Criollo Ródiz, the Clinical Diagnostics Manager at CTR Scientific, echoed this sentiment, emphasizing the company’s commitment to introducing high-value diagnostic innovations into the Mexican healthcare system. Criollo explained that their partnership with IntelliGenome would enhance the available TB diagnostic methods, particularly beneficial for children and other high-risk populations. “We are proud to support technologies that may expand access to timely and clinically meaningful TB detection in Mexico,” he added.
The CRISPR-TB test has already achieved CE-IVDD certification and holds regulatory registrations in multiple international markets, indicating a promising future for its adoption across Latin America. This partnership underscores both companies' dedication to addressing the pressing public health issue of tuberculosis, which remains a growing concern in many regions.
IntelliGenome specializes in developing cutting-edge CRISPR-based molecular diagnostics aimed at improving infectious disease detection and management, including tuberculosis. The collaboration with CTR Scientific, a renowned provider of diagnostic and laboratory solutions in Mexico, is expected to play a crucial role in advancing public health initiatives and healthcare infrastructure in the country.
In conclusion, this strategic alliance signifies a pivotal step towards enhancing TB detection and potentially transforming the lives of many individuals affected by this disease. By combining innovative technology with local expertise, IntelliGenome and CTR Scientific are poised to make a lasting impact in the fight against tuberculosis in Mexico. The relentless pursuit of improved diagnostics illustrates the potential for significant advancements in public health, paving the way for more effective and timely medical interventions for one of the world's most dangerous infectious diseases.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.